Lung immune prognostic index as a prognostic predictor in patients with advanced small cell lung cancer

Abstract

Aims: Identifying prognostic markers in advanced small-cell lung cancer (A-SCLC) patients is important. Therefore, our study aimed to evaluate the prognostic value of pretreatment lung immune prognostic index (LIPI) in A-SCLC. Methods: This was a retrospective and observational study of A-SCLC patients treated with platinum plus etoposide chemotherapy as first-line treatment. The association of LIPI with progression-free survival (PFS) and overall survival (OS) was analysed. Results: One hundred eighteen patients were included in this study and divided into three groups LIPI 0 (n=27, 22.9%), LIPI 1 (n=57, 48.3%) and LIPI 2 (n=34, 28.8%). The median PFS of LIPI groups (0/1/2) was 8.9 (95% CI 3.83-13.96), 8 (95% CI 6.41-9.58), and 5.6 (95% CI 4.60-6.60) months, respectively (p=0.1) The median OS of LIPI groups (0/1/2) was 12 (95% CI 9.11-14.88), 10.1 (95% CI 9.16-11.03), and 7.7 (95% CI 6.55-8.84) months, respectively (p=0.02). Cox regression analysis revealed that LIPI 2 score was an independent risk factor for both PFS (HR 1.839, 95% CI: 1.075-3.144, p=0.02) and OS (HR 1.757, 95% CI: 1.006-3.071, p=0.04). Conclusion: LIPI score can be used as a simple and easily accessible marker to predict prognosis for A-SCLC patients.

Keywords

• Lung immune prognostic index (LIPI)
• prognostic marker
• small-cell lung cancer (SCLC)
• systemic inflammatory indexes

References

1. Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin 2014; 24: 257–66.
2. Wang Y, Zou S, Zhao Z, Liu P, Ke C, Xu S. New insights into small-cell lung cancer development and therapy. Cell Biol Int 2020; 44: 1564–76.
3. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers 2021; 7: 3.
4. Franco F, Carcereny E, Guirado M, et al. Epidemiology, treatment, and survival in small cell lung cancer in Spain: data from the thoracic tumor registry. PLoS One 2021; 16: e02511761.
5. Dingemans AMC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32: 839–53.
6. Sun B, Hou Q, Liang Y, et al. Prognostic ability of lung immune prognostic index in limited‑stage small cell lung cancer. BMC Cancer 2022; 22: 1233.
7. Qi WX, Xiang Y, Zhao S, Chen J. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab. Cancer Immunol Immunother 2021; 70: 3199–206.
8. Huang L, Han H, Zhou L, et al. Evaluation of the lung immune prognostic index in non-small cell lung cancer patients treated with systemic therapy: a retrospective study and meta-analysis. Front Oncol 2021; 11: 670230.

9. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39–51.
10. Kalemkerian GP, Loo BW, Akerley W, et al. NCCN guidelines insights: Small cell lung cancer, Version 2.2018. J Natl Compr Canc Netw 2018; 16: 1171–82.
11. Zhang Q, Gong X, Sun L, Miao L, Zhou Y. The predictive value of pretreatment lactate dehydrogenase and derived neutrophil-to-lymphocyte ratio in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a meta-analysis. Front Oncol 2022; 12: 791496.
12. Jiang S, Wang S, Wang Q, et al. Systemic inflammation response index (SIRI) independently predicts survival in advanced lung adenocarcinoma patients treated with first-generation EGFR-TKIs. Cancer Manag Res 2021; 13: 1315–22.
13. Sonehara K, Tateishi K, Komatsu M, Yamamoto H, Hanaoka M. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer. Thorac Cancer 2020; 11: 1578–86.
14. SchnÖller L, KÄsmann L, Taugner J, Abdo R, Eze C, Manapov F. Prognostic role of lung immune scores for prediction of survival in limited-stage small cell lung cancer. In Vivo 2021; 35: 929–35.
15. Chen J, Wei S, Zhao T, Zhang X, Wang Y, Zhang X. Clinical significance of serum biomarkers in stage IV non-small-cell lung cancer treated with PD-1 inhibitors: LIPI score, NLR, dNLR, LMR, and PAB. Dis Markers 2022; 2022: 7137357.
16. Li L, Pi C, Yan X, et al. Prognostic value of the pretreatment lung immune prognostic index in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors plus chemotherapy. Front Oncol 2021; 11: 697865.
17. Qi W, Zhao S, Chen J. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy. Cancer Biomarkers 2021; 31: 177–85.
18. Minici R, Siciliano MA, Ammendola M, et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-C reactive protein ratio (LCR) in patients with hepatocellular carcinoma (HCC) undergoing chemoembolizations. Cancers (Basel) 2022; 15: 257.
19. Yang J, Deng M, Bi M, Wang Y, Qiao X. Zhang S. Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer. Futur Sci OA 2022; 8: FSO798.
20. Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med 2017; 15: 221.
21. Zhou Q, Deng G, Wang Z, Dai G. Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection. Front Surg 2023; 9: 1002075.